Phase III trial of ipilimumab in metastatic melanoma demonstrates improvement in survival

被引：0
|
作者：
不详
机构：
来源：
FUTURE ONCOLOGY | 2010年 / 6卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1208 / 1208
页数：1
相关论文
共 50 条
  • [41] Phase III randomized trial evaluating tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with advanced refractory melanoma (ILLUMINATE 301).
    Diab, Adi
    Ascierto, Paolo Antonio
    Abdel-Wahab, Reham
    Maio, Michele
    Negrier, Sylvie
    Mortier, Laurent
    Dalle, Stephane
    Krajsova, Ivana
    de la Cruz, Luis
    Leccia, Marie Therese
    Guida, Michele
    Lebbe, Celeste
    Grob, Jean-Jacques
    Butler, Marcus O.
    In, Gino Kim
    Chunduru, Srinivas
    Rahimian, Shah
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA9516 - LBA9516
  • [42] Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials
    Lebbe, Celeste
    Weber, Jeffrey S.
    Maio, Michele
    Neyns, Bart
    Harmankaya, Kaan
    Hamid, Omid
    O'Day, Steven
    Chin, Kevin M.
    McDowell, Diane Opatt
    Cykowski, Lori
    McHenry, Brent
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Ipilimumab in a Phase II trial of melanoma patients with brain metastases
    Margolin, Kim
    ONCOIMMUNOLOGY, 2012, 1 (07) : 1197 - 1199
  • [44] PHASE II STUDY OF IPILIMUMAB PLUS TEMOZOLOMIDE IN PATIENTS WITH METASTATIC MELANOMA
    Patel, S.
    Bassett, R.
    Hwu, W.
    Kim, K.
    Papadopoulos, N.
    Hwu, P.
    Bedikian, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 366 - 367
  • [45] A phase I trial of panobinostat with ipilimumab in advanced melanoma.
    Khushalani, Nikhil I.
    Markowitz, Joseph
    Eroglu, Zeynep
    Giuroiu, Iulia
    Ladanova, Viktoriya
    Reiersen, Pamela
    Rich, Jeani
    Thapa, Ram
    Schell, Michael J.
    Sotomayor, Eduardo M.
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma
    Sapna P. Patel
    Dae Won Kim
    Roland L. Bassett
    Suzanne Cain
    Edwina Washington
    Wen-Jen Hwu
    Kevin B. Kim
    Nicholas E. Papadopoulos
    Jade Homsi
    Patrick Hwu
    Agop Y. Bedikian
    Cancer Immunology, Immunotherapy, 2017, 66 : 1359 - 1366
  • [47] A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma
    Patel, Sapna P.
    Kim, Dae Won
    Bassett, Roland L.
    Cain, Suzanne
    Washington, Edwina
    Hwu, Wen-Jen
    Kim, Kevin B.
    Papadopoulos, Nicholas E.
    Homsi, Jade
    Hwu, Patrick
    Bedikian, Agop Y.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (10) : 1359 - 1366
  • [48] The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma
    Louise E Daly
    Derek G Power
    Áine O'Reilly
    Paul Donnellan
    Samantha J Cushen
    Kathleen O'Sullivan
    Maria Twomey
    David P Woodlock
    Henry P Redmond
    Aoife M Ryan
    British Journal of Cancer, 2017, 116 : 310 - 317
  • [49] The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma
    Daly, Louise E.
    Power, Derek G.
    O'Reilly, Aine
    Donnellan, Paul
    Cushen, Samantha J.
    O'Sullivan, Kathleen
    Twomey, Maria
    Woodlock, David P.
    Redmond, Henry P.
    Ryan, Aoife M.
    BRITISH JOURNAL OF CANCER, 2017, 116 (03) : 310 - 317
  • [50] A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial
    Di Giacomo, A. M.
    Ascierto, P. A.
    Pittiglio, E.
    Queirolo, P.
    Pilla, L.
    Ridolfi, R.
    Santinami, M.
    Testori, A.
    Parmiani, G.
    Maio, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S653 - S654
12345